

YOU ARE CORDIALLY INVITED TO ATTEND

# AIMOVIG® AND THE PREVENTIVE MANAGEMENT OF PATIENTS WITH MIGRAINE

## PRESENTED BY

---

HERBERT KROB, MD

## ON

---

THURSDAY, OCTOBER 17, 2019  
6:00 PM PACIFIC

## AT

---

EXCELSIOR INN RISTORANTE  
MAIN DINING ROOM  
754 EAST 13TH AVENUE  
EUGENE, OR 97401  
(541) 342-6963

## RSVP WITH YOUR LOCAL AMGEN OR NOVARTIS REPRESENTATIVE

---

TRICIA BEELER  
(541) 324-2167  
TBEELER@AMGEN.COM  
AMGEN

### INDICATION

Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

### IMPORTANT SAFETY INFORMATION

**Contraindication:** Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

**Hypersensitivity Reactions:** Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

**Adverse Reactions:** The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

**Please see accompanying Aimovig® full Prescribing Information, including Patient Product Information.**





This is not an independent medical education program and not eligible for credit toward continuing medical education requirements.

**Notice:** This event is conducted in accordance with the PhRMA Code on Interaction with Healthcare Professionals and is limited to invited healthcare professionals. Attendance by guests or spouse is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit your ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this event.

**State Laws:** To comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Vermont or Minnesota; or (2) individuals employed by prescribers in Vermont who support the provision of healthcare. You have the opportunity to opt-out of the meal.

**Disclosure by Amgen:** Amgen reports payments and transfers of value made to healthcare professionals and other healthcare related entities in accordance with federal and state laws, regulations and other transparency obligations. Any items of value provided by Amgen at this event (including the provision of meals and refreshments) may be subject to public disclosure. If you have questions regarding this matter please contact Amgen at 805-447-7422 or [HCCSpendInquiry@amgen.com](mailto:HCCSpendInquiry@amgen.com).

YOU ARE CORDIALLY INVITED TO ATTEND

# AIMOVIG® AND THE PREVENTIVE MANAGEMENT OF PATIENTS WITH MIGRAINE

## PRESENTED BY

---

HERBERT KROB, MEDICAL DOCTOR

## ON

---

THURSDAY, OCTOBER 17, 2019  
6:00 PM PACIFIC

## AT

---

EXCELSIOR INN RISTORANTE  
MAIN DINING ROOM  
754 EAST 13TH AVENUE  
EUGENE, OR 97401  
(541) 342-6963

## RSVP WITH YOUR LOCAL AMGEN OR NOVARTIS REPRESENTATIVE

---

TRICIA BEELER  
(541) 324-2167  
TBEELER@AMGEN.COM  
AMGEN

AMELIA ALBRIGHT  
+1 5036797599

AMELIAA@AMGEN.COM;

## INDICATION

Aimovig® (erenumab-aooe) is indicated for the preventive treatment of migraine in adults.

## IMPORTANT SAFETY INFORMATION

**Contraindication:** Aimovig® is contraindicated in patients with serious hypersensitivity to erenumab-aooe or to any of the excipients. Reactions have included anaphylaxis and angioedema.

**Hypersensitivity Reactions:** Hypersensitivity reactions, including rash, angioedema, and anaphylaxis, have been reported with Aimovig® in post marketing experience. Most reactions were not serious and occurred within hours of administration, although some occurred more than one week after administration. If a serious or severe reaction occurs, discontinue Aimovig® and initiate appropriate therapy.

**Adverse Reactions:** The most common adverse reactions in clinical studies (≥ 3% of Aimovig®-treated patients and more often than placebo) were injection site reactions and constipation.

**Please see accompanying Aimovig® full Prescribing Information, including Patient Product Information.**





This is not an independent medical education program and not eligible for credit toward continuing medical education requirements.

**Notice:** This event is conducted in accordance with the PhRMA Code on Interaction with Healthcare Professionals and is limited to invited healthcare professionals. Attendance by guests or spouse is not appropriate. Government employees are subject to state and federal laws and ethics rules that may limit your ability to receive any gifts, including meals, from pharmaceutical companies. If you are a state or federal employee, it is your responsibility to seek guidance and prior approval from your employer or site ethics counselor to attend this event.

**State Laws:** To comply with law and Amgen policies, Amgen is unable to offer food and beverages to (1) individuals with prescribing authority in Vermont or Minnesota; or (2) individuals employed by prescribers in Vermont who support the provision of healthcare. You have the opportunity to opt-out of the meal.

**Disclosure by Amgen:** Amgen reports payments and transfers of value made to healthcare professionals and other healthcare related entities in accordance with federal and state laws, regulations and other transparency obligations. Any items of value provided by Amgen at this event (including the provision of meals and refreshments) may be subject to public disclosure. If you have questions regarding this matter please contact Amgen at 805-447-7422 or [HCCSpendInquiry@amgen.com](mailto:HCCSpendInquiry@amgen.com).